{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:00:20Z","timestamp":1791295220314,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA247648"],"award-info":[{"award-number":["U24CA247648"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","award":["UM1CA186709"],"award-info":[{"award-number":["UM1CA186709"]}],"id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM066691"],"award-info":[{"award-number":["T32GM066691"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.heliyon.2023.e20972","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T02:43:37Z","timestamp":1697165017000},"page":"e20972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring pharmacokinetics of talazoparib in ABCB1\/ABCG2-deficient mice using a novel UHPLC-MS\/MS method"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-5160","authenticated-orcid":false,"given":"Zahra","family":"Talebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7250-9346","authenticated-orcid":false,"given":"Dominique A.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-675X","authenticated-orcid":false,"given":"Eric D.","family":"Eisenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalindi","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":false,"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5739-6868","authenticated-orcid":false,"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-3362","authenticated-orcid":false,"given":"Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.heliyon.2023.e20972_bib1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e20972_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"18","key":"10.1016\/j.heliyon.2023.e20972_bib3","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e20972_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.heliyon.2023.e20972_bib5","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e20972_bib6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, dose-Escalation, two-Part Trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e20972_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/jcph.1415","article-title":"A phase 1 mass balance study of (14) C-labeled talazoparib in patients with advanced solid tumors","volume":"59","author":"Yu","year":"2019","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e20972_bib8","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1002\/jcp.29552","article-title":"Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer","volume":"235","author":"Guney Eskiler","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e20972_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/jcph.1520","article-title":"Population pharmacokinetics of talazoparib in patients with advanced cancer","volume":"60","author":"Yu","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e20972_bib10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/jcph.1626","article-title":"Exposure-safety analyses of talazoparib in patients with advanced breast cancer and germline BRCA1\/2 mutations in the EMBRACA and ABRAZO trials","volume":"60","author":"Elmeliegy","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e20972_bib11","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/jcph.1623","article-title":"Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1\/2 mutations in the EMBRACA trial","volume":"60","author":"Yu","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e20972_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2147\/DDDT.S239458","article-title":"Metabolic stability assessment of new PARP inhibitor talazoparib using validated LC-MS\/MS methodology: in silico metabolic vulnerability and toxicity studies","volume":"14","author":"Attwa","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e20972_bib13","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.52711\/0974-360X.2022.00433","article-title":"Novel LC\u2013MS method development and validation for characterization of talazoparib, an anti-cancer drug and its forced degradation behavior","volume":"15","author":"Pakalapati","year":"2022","journal-title":"Res. J. Pharm. Technol."},{"key":"10.1016\/j.heliyon.2023.e20972_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121925","article-title":"Development and validation of an integrated LC-MS\/MS assay for therapeutic drug monitoring of five PARP-inhibitors","volume":"1138","author":"Bruin","year":"2020","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.heliyon.2023.e20972_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112850","article-title":"UPLC-MS\/MS method for the determination of talazoparib in rat plasma and its pharmacokinetic study","volume":"177","author":"Ye","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"20","key":"10.1016\/j.heliyon.2023.e20972_bib16","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3056","article-title":"Murine pharmacokinetic studies","volume":"8","author":"Leblanc","year":"2018","journal-title":"Bio-protocol"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e20972_bib17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1634\/stemcells.2005-0150","article-title":"Contribution of the ABC transporters Bcrp1 and Mdr1a\/1b to the side population phenotype in mammary gland and bone marrow of mice","volume":"23","author":"Jonker","year":"2005","journal-title":"Stem Cell."},{"issue":"14","key":"10.1016\/j.heliyon.2023.e20972_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23148037","article-title":"Preclinical assessment of the combination of PSMA-targeting radionuclide therapy with PARP inhibitors for prostate cancer treatment","volume":"23","author":"Ruigrok","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e20972_bib19","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1158\/1535-7163.MCT-17-0365","article-title":"Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma","volume":"16","author":"Kizilbash","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e20972_bib20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.18433\/J3QP4W","article-title":"Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan","volume":"10","author":"Su","year":"2007","journal-title":"J Pharm Pharm Sci"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e20972_bib21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/00498254.2019.1708514","article-title":"Usefulness of novobiocin as a selective inhibitor of intestinal breast cancer resistance protein (Bcrp) in rats","volume":"50","author":"Suzuki","year":"2020","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e20972_bib23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bcp.14178","article-title":"Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours","volume":"86","author":"Elmeliegy","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e20972_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/ol.2023.13747","article-title":"Transporter\u2011mediated drug\u2011drug interactions involving poly (ADP\u2011ribose) polymerase inhibitors (Review)","volume":"25","author":"Zhao","year":"2023","journal-title":"Oncol. Lett."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e20972_bib24","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/jps.20963","article-title":"Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)","volume":"96","author":"Gupta","year":"2007","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e20972_bib25","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1128\/AAC.02931-15","article-title":"Inhibitory potential of antifungal drugs on ATP-binding cassette transporters P-glycoprotein, MRP1 to MRP5, BCRP, and BSEP","volume":"60","author":"Lempers","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e20972_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/dmd.115.067744","article-title":"Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters","volume":"44","author":"Vermeer","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"21","key":"10.1016\/j.heliyon.2023.e20972_bib27","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.7150\/thno.36281","article-title":"A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e20972_bib28","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat. Cancer"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402308180X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402308180X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:18:19Z","timestamp":1791292699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402308180X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S240584402308180X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20972","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring pharmacokinetics of talazoparib in ABCB1\/ABCG2-deficient mice using a novel UHPLC-MS\/MS method","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e20972"}}